Skip to main content
Premium Trial:

Request an Annual Quote

Genomic Solutions Abandons Plans to Develop Mass Spectrometer Business

NEW YORK, Oct 6 - Genomic Solutions said Friday it was embarking on a strategy that would include designing a proteomics system to integrate data collected by mass spectrometers made by all major manufacturers while discontinuing production of its own mass spectrometry machines.

“We're giving customers freedom of choice, rather than forcing them to discontinue use of their current mass spec because they must buy one from a single vendor if they wish to have an integrated system,” Christine Ethier, Genomic Solutions' vice president of proteomics said in a statement. “Customers can have the peace of mind in knowing that our Investigator system will integrate with any MALDI, LC/MS/MS or ion trap mass spec from any of the major manufacturers.''

The company said that it would continue to improve and add new consumables and software, while selling its MALDI-TOF system and intellectual property to Thermo Electron.

In exchange, Genomic Solutions said it would receive an undisclosed amount of cash and other considerations. Thermo Electron has also agreed to integrate the Investigator Proteomic System into their mass spectrometers.

Genomic Solutions, which was not immediately available for comment, did not explain how it would develop the Investigator Proteomics System so that it would be compatible with a variety of mass spectrometer protocols.

Genomic Solutions did, however, announce that its latest addition to its Investigator Proteomic System, Protein Warehouse, was able to integrate all current Investigator component data from the company's individual proteomics instruments.

These instruments include 2D electrophoresis system, gel processor, automated stainer, image acquisition system, ProPic fluorescent automated protein spot excision robot, ProGest digestion station, and ProMS MALDI preparation station.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.